Teva Pharmaceutical Industries Ltd. TEVA announces the launch of the
generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in
the United States.
Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of
approximately $852 million in the United States, according to IMS data as of
December 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
